Study on Pharmacokinetics of Newly Developed ANtiretroviral Agents in HIV-infected pregNAnt Women (PANNA)

Trial Profile

Study on Pharmacokinetics of Newly Developed ANtiretroviral Agents in HIV-infected pregNAnt Women (PANNA)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Abacavir (Primary) ; Atazanavir (Primary) ; Darunavir (Primary) ; Emtricitabine (Primary) ; Enfuvirtide (Primary) ; Etravirine (Primary) ; Fosamprenavir (Primary) ; Indinavir (Primary) ; Maraviroc (Primary) ; Raltegravir (Primary) ; Rilpivirine (Primary) ; Ritonavir (Primary) ; Tenofovir disoproxil fumarate (Primary) ; Tipranavir (Primary)
  • Indications HIV infections
  • Focus Pharmacokinetics
  • Acronyms PANNA
  • Most Recent Events

    • 16 Feb 2017 Results presented at the 24th Conference on Retroviruses and Opportunistic Infections
    • 15 Sep 2016 Planned End Date changed from 1 Dec 2017 to 1 Dec 2020.
    • 15 Sep 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top